Abstract
Physicians in the world never stop pursuing the best approach for patients. We are pleased to participate in a debate on what is the most optimal management for stage IIIA non-small cell lung cancer (NSCLC), which is well known for heterogeneity of diseases and complexity of treatment options.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
